Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people

of NHS resources. So, icosapent ethyl is recommended for secondary prevention in people with LDL-C levels above 1.04 mmol/litre and below or equal to 2.60 mmol/litre. People must be taking a statin to have icosapent ethyl. People who cannot have statins are not covered by icosapent ethyl's marketing authorisation, so NICE cannot make any recommendations in this area. 2 Information about icosapent ethyl Marketing authorisation indication 2.1 Icosapent ethyl (Vazkepa, Amarin Corporation) is indicated 'to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides (≥150 mg/dL [1.7mmol/l]) and: • established cardiovascular disease, or • diabetes, and at least on other cardiovascular risk factor'. Dosage in the marketing authorisation 2.2 The dosage schedule is available in the summary of product characteristics for icosapent ethyl. Price 2.3 Icosapent ethyl costs £144.21 per pack of 120 capsules (excluding VAT; company submission). Costs may vary in different settings because of negotiated procurement discounts. 3 Committee discussion The appraisal committee considered evidence submitted by Amarin, a review of this submission by the evidence review group (ERG), and responses from stakeholders. See the committee papers for full details of the evidence. Treatment pathway and comparator People with elevated
